Bloomsbury Genetic Therapies ("Bloomsbury") is a clinical-stage biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies. The Company was spun out of University College London and launched in October 2022 with funding from UCL Technology Fund. Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs.
Company Details
- Employees
- 3
- Founded
- -
- Address
- London, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://bloomsburygtx.com
- Keywords
- Spur Therapeutics.
- HQ
- London
Bloomsbury Genetic Therapies Questions
Bloomsbury Genetic Therapies's website is https://bloomsburygtx.com
Bloomsbury Genetic Therapies's LinkedIn profile is https://uk.linkedin.com/company/bloomsburygtx
Bloomsbury Genetic Therapies has
3 employees.
View email and phone details for 3
employees at Bloomsbury Genetic Therapies.
Bloomsbury Genetic Therapies's industry is
Biotechnology Research
Bloomsbury Genetic Therapies's top competitors are
Sania Therapeutics,
Mitorx Therapeutics,
Achilles Therapeutics Plc,
Spur Therapeutics,
Ucl Business Ltd,
Orchard Therapeutics - U.s.,
Yellowstone Biosciences,
Metabolic Support Uk,
Albionvc,
Quell Therapeutics.
Bloomsbury Genetic Therapies's categories are Biotechnology Research
Bloomsbury Genetic Therapies's founding year is 2021
